|
04 Mar 2020 |
DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease
|
|
04 Mar 2020 |
Amunix Raises $73 Million in Series A Financing Led by Omega Funds
|
|
04 Mar 2020 |
Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology
|
|
04 Mar 2020 |
Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19
|
|
04 Mar 2020 |
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite
|
|
04 Mar 2020 |
Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure
|
|
04 Mar 2020 |
Heat Biologics Launches Program to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus
|
|
04 Mar 2020 |
Inovio accelerates timeline for COVID-19 DNA vaccine INO-4800
|
|
04 Mar 2020 |
Janssen Submits European Marketing Authorisation Application for Ponesimod for Treatment of Adults with Relapsing Multiple Sclerosis
|
|
04 Mar 2020 |
FDA Grants Breakthrough Therapy Designation for Genentech’s Esbriet (pirfenidone) in Unclassifiable Interstitial Lung Disease
|
|
04 Mar 2020 |
EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance
|
|
04 Mar 2020 |
Iktos and SRI International Announce Collaboration to Combine Artificial Intelligence and Novel Automated Discovery Platform for Accelerated Development of New Anti-Viral Therapies
|
|
04 Mar 2020 |
Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study
|
|
04 Mar 2020 |
Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19
|
|
04 Mar 2020 |
PureTech Announces First Participant Dosed in Clinical Trial of Wholly-Owned Lymphedema Candidate LYT-100
|
|
04 Mar 2020 |
MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours
|
|
04 Mar 2020 |
Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10
|
|
04 Mar 2020 |
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
|
|
04 Mar 2020 |
Alnylam Announces Approval of GIVLAARI® (givosiran) in the European Union for the Treatment of Acute Hepatic Porphyria (AHP) in Adults and Adolescents
|
|
03 Mar 2020 |
Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease
|
